{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:05Z","timestamp":1786997885674,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.vaccine.2011.12.128","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T19:47:57Z","timestamp":1326138477000},"page":"1841-1846","source":"Crossref","is-referenced-by-count":5,"title":["Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network"],"prefix":"10.1016","volume":"30","author":[{"given":"Brock","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Rose, Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome I.","family":"Tokars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Franzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"RR\u20136","key":"10.1016\/j.vaccine.2011.12.128_bib0005","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (2009)","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0010","unstructured":"Food and Drug Administration. Biothrax. Available at http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm133822.htm. Accessed November 10, 2010."},{"issue":"13","key":"10.1016\/j.vaccine.2011.12.128_bib0015","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0020","unstructured":"Institute of Medicine.\u201cThe Anthrax Vaccine. Is It Safe? Does It Work?\u201d Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-Up Agency. Washington, DC: National Academy Press 2002."},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.128_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/exmp.2002.2429","article-title":"Antibodies to squalene in recipients of anthrax vaccine","volume":"73","author":"Asa","year":"2002","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.128_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1385\/NMM:9:1:83","article-title":"Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice","volume":"9","author":"Petrik","year":"2007","journal-title":"Neuromolecular Med"},{"issue":"1","key":"10.1016\/j.vaccine.2011.12.128_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/milmed\/167.1.74","article-title":"Delayed-type hypersensitivity reaction to anthrax vaccine","volume":"167","author":"Greidanus","year":"2002","journal-title":"Mil Med"},{"issue":"3","key":"10.1016\/j.vaccine.2011.12.128_bib0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.vaccine.2005.07.105","article-title":"Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL\/6 mice","volume":"24","author":"Prater","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2011.12.128_bib0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bdrb.20205","article-title":"Reproductive toxicity of BioThrax\u00ae in rabbits","volume":"86","author":"Franco","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"9","key":"10.1016\/j.vaccine.2011.12.128_bib0050","first-page":"433","article-title":"Detecting biothreat agents: the Laboratory Response Network","volume":"69","author":"Morse","year":"2003","journal-title":"ASM News"},{"issue":"7","key":"10.1016\/j.vaccine.2011.12.128_bib0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/milmed\/165.suppl_2.28","article-title":"A national laboratory network for bioterrorism: evolution from a prototype network of laboratories performing routine surveillance","volume":"165","author":"Gilchrist","year":"2000","journal-title":"Mil Med"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0060","unstructured":"Centers for Disease Control and Prevention. Notice to readers: Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2002; 51(45):1024\u20131026."},{"key":"10.1016\/j.vaccine.2011.12.128_bib0065","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pds.1302","article-title":"Factors influencing laboratory workers\u2019 decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's Anthrax Vaccination Program","volume":"15","author":"Fowler","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0070","unstructured":"Anthrax Vaccine Adsorbed (BIOTHRAX\u2122) Package Insert. 2002. Manufactured by Bioport Corporation, Lansing Michigan, US Lic No. 1260."},{"key":"10.1016\/j.vaccine.2011.12.128_bib0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"Brit Med J"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0080","series-title":"SF-36 health survey manual and interpretation guide","author":"Ware","year":"2000"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0085","unstructured":"R Development Core Team (2010). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http:\/\/www.R-project.org."},{"key":"10.1016\/j.vaccine.2011.12.128_bib0090","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/ard.2003.010769","article-title":"Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study","volume":"63","author":"Picavet","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/pds.1166","article-title":"Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community","volume":"15","author":"Tang","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2011.12.128_bib0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.amepre.2006.12.015","article-title":"Anthrax vaccination in the Millennium Cohort: validation and measures of health","volume":"32","author":"Smith","year":"2007","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.vaccine.2011.12.128_bib0110","first-page":"43","article-title":"Measurement comparisons of the Medical Outcomes Study and Veterans SF-36\u00ae health survey","volume":"25","author":"Kazis","year":"2004","journal-title":"Health Care Financing Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11020895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T04:04:34Z","timestamp":1561176274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11020895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0264410X11020895"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.128","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}